Summit Therapeutics Inc
NASDAQ:SMMT
Summit Therapeutics Inc
NASDAQ:SMMT
Price:
16.07
USD
3.95%
Market Cap:
$12.5B
Income Statement
Earnings Waterfall
Summit Therapeutics Inc
Summit Therapeutics Inc
Income Statement
Summit Therapeutics Inc
Summit Therapeutics Inc
Currency: USD
| Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
4
|
13
|
15
|
18
|
16
|
9
|
8
|
9
|
0
|
0
|
|
| Revenue |
1
N/A
|
1
+2%
|
1
+5%
|
1
+28%
|
1
-15%
|
1
-15%
|
2
+182%
|
2
+3%
|
2
+3%
|
2
+10%
|
1
-53%
|
1
-26%
|
0
-35%
|
0
-52%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | ||||||||||||||||||||||
| Operating Expenses |
(23)
|
(32)
|
(41)
|
(53)
|
(64)
|
(72)
|
(75)
|
(88)
|
(93)
|
(82)
|
(79)
|
(64)
|
(588)
|
(590)
|
(585)
|
(89)
|
(101)
|
(154)
|
(211)
|
(250)
|
(759)
|
|
| Selling, General & Administrative |
(8)
|
(12)
|
(16)
|
(19)
|
(23)
|
(23)
|
(22)
|
(24)
|
(26)
|
(27)
|
(27)
|
(27)
|
(27)
|
(26)
|
(26)
|
(30)
|
(31)
|
(46)
|
(61)
|
(64)
|
(411)
|
|
| Research & Development |
(34)
|
(36)
|
(40)
|
(52)
|
(58)
|
(68)
|
(75)
|
(84)
|
(88)
|
(73)
|
(70)
|
(51)
|
(562)
|
(563)
|
(561)
|
(59)
|
(71)
|
(93)
|
(151)
|
(171)
|
(348)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Operating Expenses |
20
|
17
|
15
|
19
|
18
|
20
|
21
|
21
|
20
|
17
|
18
|
14
|
2
|
(1)
|
2
|
1
|
1
|
(15)
|
0
|
(15)
|
0
|
|
| Operating Income |
(22)
N/A
|
(31)
-39%
|
(41)
-32%
|
(52)
-28%
|
(63)
-20%
|
(71)
-13%
|
(74)
-4%
|
(86)
-17%
|
(91)
-6%
|
(80)
+12%
|
(78)
+3%
|
(64)
+18%
|
(587)
-823%
|
(590)
-1%
|
(585)
+1%
|
(89)
+85%
|
(101)
-14%
|
(154)
-52%
|
(211)
-37%
|
(250)
-19%
|
(759)
-203%
|
|
| Pre-Tax Income | ||||||||||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
(0)
|
0
|
(0)
|
0
|
(2)
|
(3)
|
(3)
|
(3)
|
(7)
|
(14)
|
(13)
|
(13)
|
(5)
|
(2)
|
1
|
5
|
10
|
13
|
|
| Non-Reccuring Items |
0
|
0
|
(1)
|
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(8)
|
0
|
0
|
(8)
|
(521)
|
(15)
|
0
|
(15)
|
0
|
0
|
|
| Total Other Income |
3
|
3
|
2
|
0
|
(2)
|
(2)
|
(1)
|
0
|
1
|
(2)
|
(6)
|
0
|
1
|
5
|
9
|
(0)
|
(0)
|
0
|
0
|
0
|
(0)
|
|
| Pre-Tax Income |
(19)
N/A
|
(28)
-45%
|
(39)
-41%
|
(53)
-34%
|
(64)
-22%
|
(73)
-14%
|
(75)
-2%
|
(89)
-18%
|
(93)
-4%
|
(85)
+8%
|
(87)
-2%
|
(79)
+9%
|
(600)
-661%
|
(598)
+0%
|
(598)
+0%
|
(615)
-3%
|
(118)
+81%
|
(153)
-30%
|
(221)
-44%
|
(241)
-9%
|
(746)
-210%
|
|
| Net Income | ||||||||||||||||||||||
| Tax Provision |
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(19)
|
(28)
|
(39)
|
(53)
|
(64)
|
(73)
|
(75)
|
(89)
|
(93)
|
(85)
|
(87)
|
(79)
|
(600)
|
(598)
|
(598)
|
(615)
|
(118)
|
(153)
|
(221)
|
(241)
|
(746)
|
|
| Net Income (Common) |
(19)
N/A
|
(28)
-45%
|
(39)
-41%
|
(53)
-35%
|
(64)
-21%
|
(73)
-14%
|
(75)
-3%
|
(89)
-18%
|
(93)
-4%
|
(85)
+8%
|
(87)
-2%
|
(79)
+9%
|
(600)
-661%
|
(598)
+0%
|
(598)
+0%
|
(615)
-3%
|
(118)
+81%
|
(153)
-30%
|
(221)
-44%
|
(241)
-9%
|
(746)
-210%
|
|
| EPS (Diluted) |
-0.28
N/A
|
-0.41
-46%
|
-0.58
-41%
|
-0.76
-31%
|
-0.77
-1%
|
-0.8
-4%
|
-0.76
+5%
|
-0.96
-26%
|
-0.94
+2%
|
-0.87
+7%
|
-0.58
+33%
|
-0.41
+29%
|
-1.58
-285%
|
-0.85
+46%
|
-0.85
N/A
|
-0.99
-16%
|
-0.17
+83%
|
-0.21
-24%
|
-0.31
-48%
|
-0.33
-6%
|
-1.01
-206%
|
|
Switch to:
Switch to:
See Also
Discover More
